These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Implantable cardioverter-defibrillators for treatment of sustained ventricular arrhythmias in patients with Chagas' heart disease: comparison with a control group treated with amiodarone alone. Gali WL; Sarabanda AV; Baggio JM; Ferreira LG; Gomes GG; Marin-Neto JA; Junqueira LF Europace; 2014 May; 16(5):674-80. PubMed ID: 24481778 [TBL] [Abstract][Full Text] [Related]
26. Influence of diabetes mellitus on inappropriate and appropriate implantable cardioverter-defibrillator therapy and mortality in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT) Trial. Ruwald MH; Zareba W; Jons C; Zhang C; Ruwald AC; Olshansky B; McNitt S; Bloch Thomsen PE; Shoda M; Merkely B; Moss AJ; Kutyifa V Circulation; 2013 Aug; 128(7):694-701. PubMed ID: 23881862 [TBL] [Abstract][Full Text] [Related]
27. Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: results from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) trial. Ruwald MH; Solomon SD; Foster E; Kutyifa V; Ruwald AC; Sherazi S; McNitt S; Jons C; Moss AJ; Zareba W Circulation; 2014 Dec; 130(25):2278-86. PubMed ID: 25301831 [TBL] [Abstract][Full Text] [Related]
28. Cardiac Resynchronization Therapy Reduces Ventricular Arrhythmias in Primary but Not Secondary Prophylactic Implantable Cardioverter Defibrillator Patients: Insight From the Resynchronization in Ambulatory Heart Failure Trial. Sapp JL; Parkash R; Wells GA; Yetisir E; Gardner MJ; Healey JS; Thibault B; Sterns LD; Birnie D; Nery PB; Sivakumaran S; Essebag V; Dorian P; Tang AS Circ Arrhythm Electrophysiol; 2017 Mar; 10(3):. PubMed ID: 28292754 [TBL] [Abstract][Full Text] [Related]
29. The implantable cardioverter defibrillator and primary prevention of sudden death: the Multicenter Automatic Defibrillator Implantation Trial and the Coronary Artery Bypass Graft (CABG)-Patch Trial. Block M; Breithardt G Am J Cardiol; 1999 Mar; 83(5B):74D-78D. PubMed ID: 10089844 [TBL] [Abstract][Full Text] [Related]
30. Implantable devices versus antiarrhythmic drug therapy in recurrent ventricular tachycardia and ventricular fibrillation. Hohnloser SH Am J Cardiol; 1999 Nov; 84(9A):56R-62R. PubMed ID: 10568661 [TBL] [Abstract][Full Text] [Related]
31. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients. Alsheikh-Ali AA; Link MS; Semsarian C; Shen WK; Estes NA; Maron MS; Haas TS; Formisano F; Boriani G; Spirito P; Maron BJ Heart Rhythm; 2013 Feb; 10(2):214-8. PubMed ID: 23041573 [TBL] [Abstract][Full Text] [Related]
32. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). Singh JP; Hall WJ; McNitt S; Wang H; Daubert JP; Zareba W; Ruskin JN; Moss AJ; J Am Coll Cardiol; 2005 Nov; 46(9):1712-20. PubMed ID: 16256874 [TBL] [Abstract][Full Text] [Related]
33. Incidence of and predictors for appropriate implantable cardioverter-defibrillator therapy in patients with a secondary preventive implantable cardioverter-defibrillator indication. Schaer B; Kühne M; Reichlin T; Osswald S; Sticherling C Europace; 2016 Feb; 18(2):227-31. PubMed ID: 26063686 [TBL] [Abstract][Full Text] [Related]
34. Long-Term Clinical Outcome of Arrhythmogenic Right Ventricular Cardiomyopathy in Individuals With a p.S358L Mutation in TMEM43 Following Implantable Cardioverter Defibrillator Therapy. Hodgkinson KA; Howes AJ; Boland P; Shen XS; Stuckless S; Young TL; Curtis F; Collier A; Parfrey PS; Connors SP Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):. PubMed ID: 26966288 [TBL] [Abstract][Full Text] [Related]
35. Implantable cardioverter defibrillators in arrhythmogenic right ventricular dysplasia/cardiomyopathy: patient outcomes, incidence of appropriate and inappropriate interventions, and complications. Schinkel AF Circ Arrhythm Electrophysiol; 2013 Jun; 6(3):562-8. PubMed ID: 23673907 [TBL] [Abstract][Full Text] [Related]
36. [Long-term outcome of pharmacological and nonpharmacological treatment for ventricular arrhythmias]. Ohnishi S; Kasanuki H J Cardiol; 2000 Mar; 35 Suppl 1():75-84. PubMed ID: 10834174 [TBL] [Abstract][Full Text] [Related]
37. Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single-center study. Giorgberidze I; Saksena S; Krol RB; Munsif AN; Kolettis T; Mathew P; Varanasi S; Prakash A; Delfaut P; Lewis CB Am J Cardiol; 1997 Sep; 80(5B):3F-9F. PubMed ID: 9291444 [TBL] [Abstract][Full Text] [Related]
39. Drugs versus devices in controlling ventricular tachycardia, ventricular fibrillation, and recurrent cardiac arrest. Haverkamp W; Eckardt L; Borggrefe M; Breithardt G Am J Cardiol; 1997 Oct; 80(8A):67G-73G. PubMed ID: 9354413 [TBL] [Abstract][Full Text] [Related]
40. Quality of life in the Canadian Implantable Defibrillator Study (CIDS). Irvine J; Dorian P; Baker B; O'Brien BJ; Roberts R; Gent M; Newman D; Connolly SJ Am Heart J; 2002 Aug; 144(2):282-9. PubMed ID: 12177646 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]